MEDP vs. INCY, CRL, EXEL, LH, NRC, PGEN, LUNA, PIRS, ICLR, and IQV
Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include Incyte (INCY), Charles River Laboratories International (CRL), Exelixis (EXEL), Laboratory Co. of America (LH), National Research (NRC), Precigen (PGEN), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), ICON Public (ICLR), and IQVIA (IQV).
Medpace (NASDAQ:MEDP) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
In the previous week, Medpace had 6 more articles in the media than Incyte. MarketBeat recorded 15 mentions for Medpace and 9 mentions for Incyte. Incyte's average media sentiment score of 0.87 beat Medpace's score of 0.64 indicating that Incyte is being referred to more favorably in the news media.
Medpace presently has a consensus price target of $382.00, suggesting a potential upside of 1.53%. Incyte has a consensus price target of $76.07, suggesting a potential upside of 46.52%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Medpace.
78.0% of Medpace shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Comparatively, 17.5% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Incyte received 873 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 73.66% of users gave Incyte an outperform vote while only 63.72% of users gave Medpace an outperform vote.
Incyte has higher revenue and earnings than Medpace. Incyte is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Incyte has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Incyte has a net margin of 16.17% compared to Medpace's net margin of 15.00%. Medpace's return on equity of 63.98% beat Incyte's return on equity.
Summary
Medpace and Incyte tied by winning 9 of the 18 factors compared between the two stocks.
Get Medpace News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
